Entera Bio Ltd. ENTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +64.95%
- 1 year
- +13.48%
- Open
- 3.02
- Prev close
- 3.12
- Mkt cap
- 556.55M
- Vol
- 292.68K
- Avg vol
- 504.79K
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.95
- High
- 3.24
- Forward P/E
- -3.64
- Beta
- 0.00
- Short ratio
- 0.54
- Inst. own
- 18.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.84
- 200-d avg
- 1.90
- 1y target
- 10.00
5D chart
Signals (51)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:35 PM | 2 days ago |
| RSI: Overbought | Oct 30, 1:00 PM | 2 days ago |
| RSI: Overbought | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:50 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
News
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
2 days ago benzinga.com
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
5 days ago globenewswire.com
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of…
-
2 weeks ago benzinga.com
Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5…
2 weeks ago globenewswire.com
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
3 weeks ago benzinga.com
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
3 weeks ago globenewswire.com
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional…
3 weeks ago globenewswire.com
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of…
-
1 month ago benzinga.com
Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
-
1 month ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
1 month ago benzinga.com
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
1 month ago benzinga.com
Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures mixed; Oxford Industries fell 12.6% after mixed results. Lululemon, Guidewire, Asana and UiPath also dropped premarket.
2 months ago globenewswire.com
Correction: Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief…
2 months ago globenewswire.com
Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief…
-
2 months ago benzinga.com
Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
2 months ago globenewswire.com
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens…
2 months ago marketbeat.com
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled…
2 months ago globenewswire.com
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with…
2 months ago globenewswire.com
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase…
3 months ago globenewswire.com
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company's Chief…
3 months ago prnewswire.com
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd.
3 months ago benzinga.com
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Entera Bio Ltd. (NASDAQ:ENTX) shares traded higher Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
3 months ago benzinga.com
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consumer staples up 2%, tech down 1.9%. Durable goods orders rise 0.3%.
3 months ago benzinga.com
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.
3 months ago globenewswire.com
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for…
3 months ago zacks.com
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
4 months ago globenewswire.com
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet,…
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regular session. The market value of their outstanding shares is at $4.0 million. Aditxt (NASDAQ:ADTX) shares…
4 months ago globenewswire.com
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to…
-
4 months ago benzinga.com
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected…
4 months ago globenewswire.com
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected…
4 months ago globenewswire.com
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026
7 months ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)
Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures rose on Monday following Friday’s sharp sell-off. Futures of the major…
7 months ago benzinga.com
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
9 months ago benzinga.com
OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilitiesThe companies have accelerated this program and aim to…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
-
3 years ago benzinga.com
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
-
3 years ago benzinga.com
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
-
3 years ago benzinga.com
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 413 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 101 companies made new 52-week lows.
-
4 years ago benzinga.com
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.